CERo Therapeutics(CERO) - 2022 Q4 - Annual Report
CERo Therapeutics(CERO)2023-03-24 07:43
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40877 PHOENIX BIOTECH ACQUISITION CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-1088814 (St ...